What Дицетел Treats: Main Uses and Benefits

Дицетел (Pinaverium Bromide) is commonly used to help provide symptomatic relief for conditions involving excessive muscle contractions in the digestive tract, offering support that helps ease the overall burden of uncomfortable symptoms. It is often applied across conditions characterized by episodic or fluctuating manifestations.

---

Easing Irritable Bowel Syndrome (IBS) Symptoms

The primary therapeutic focus is managing symptoms associated with Irritable Bowel Syndrome (IBS), functional gastrointestinal motility disorders, and functional disorders of the biliary tract. Clinical use is relevant when patients experience recurring abdominal pain, painful cramping, distension, and bloating. This medication is used for managing groups of symptoms that may become intense or disruptive, helping patients cope more steadily with difficult episodes.

---

Reducing Visceral Spasm and Discomfort

It assists with maintaining functional stability by easing symptoms that create noticeable functional strain. It is applied in addressing functional scenarios where short-term symptomatic assistance is needed, such as for preparation before certain diagnostic procedures.

---

Quick Fact: Relief for Functional Spasms

Property	Description
Targeted Relief	Visceral abdominal pain and cramping
Key Indication	Irritable Bowel Syndrome (IBS)
Primary Benefit	Easing overall symptom burden and supporting functional stability
Typical Scenario	Managing recurrent, episodic discomfort

Regulatory References

1. FDA Verified Product Information

Who Can and Cannot Use Dicetel (Pinaverium Bromide)?

This medication is approved for use in adults but is subject to several official restrictions and prohibitions defined in regulatory documents.

Contraindications and Prohibitions

Dicetel is strictly contraindicated for use if you have a known hypersensitivity or allergy to pinaverium bromide or any other components of the tablet. Additionally, use is prohibited for patients with specific rare hereditary sugar problems, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, due to the presence of lactose.

Restricted and Non-Recommended Groups

Population Group	Regulatory Status	Key Restriction/Reason
Children	Not Recommended	Safety and efficacy have not been established; limited experience.
Breastfeeding Women	Should Not Be Used	Insufficient data on excretion in milk; risk to infant cannot be excluded.
Pregnant Women	Conditional Use	Only to be administered if essential to the patient's welfare (safety not established).
Esophageal Conditions	Special Attention Required	Use in patients with esophageal lesions or hiatus hernia requires careful administration to prevent lesions.
Underlying Organic Disease	Prohibited	Must not be used for motility issues caused by an underlying organic, non-functional disease.

Eligibility is defined by official exclusion criteria. The medicine should only be used by the established adult population when no contraindications or prohibitions are present.

Interactions with other Medicines and Products

Clinical data on the spasmolytic agent Дицетел (Pinaverium bromide) indicate a limited profile of documented drug-drug interactions. Authoritative regulatory information establishes a lack of interference with several major classes of co-administered medications.

Specific findings from controlled clinical studies demonstrate the absence of any interaction with common therapeutic agents, including:

• Digitalis drugs (Cardiac Glycosides)
• Oral Anti-Diabetics and Insulin
• Oral Anticoagulants (such as acenocoumarol, a vitamin K antagonist) and Heparin

These results suggest that Дицетел does not significantly impact the activity or action of these medications, which is relevant for patients managing chronic conditions. There is one documented pharmacodynamic interaction with a specific drug class: the co-administration of an anticholinergic drug may enhance spasmolysis, meaning the combined effect could lead to a stronger antispasmodic result. Additionally, regulatory sources state that no interference was observed between Дицетел and standard laboratory tests used for drug level detection.

It is important for patients to discuss all prescription and over-the-counter products with their healthcare provider, as potential interactions should always be assessed on an individual basis, especially when combining medications that affect gastrointestinal motility or blood pressure.

The mechanism of action for Дицетел (Pinaverium Bromide) is characterized by its highly selective and localized effects on the smooth muscle cells of the digestive system, achieved through targeted ion channel interference.

Selective Blockade of Calcium Channels

The drug's primary function is to act as a non-competitive antagonist at the L-type Voltage-Gated Calcium Channels ( Cav1.2) on the smooth muscle cell membrane. This mechanism prevents the crucial influx of extracellular calcium ions ( Ca^2+) into the cell cytoplasm. This selective molecular blockade is the first step in the cascade, localizing the drug's effect to the gut.

Disruption of Excitation-Contraction Coupling

By limiting the availability of Ca^2+, the drug interrupts the fundamental Excitation-Contraction Coupling Pathway required for muscle fibers to shorten. This disruption results directly in widespread Gastrointestinal Smooth Muscle Relaxation. This physiological change leads to a decrease in muscle excitability and supports modulation of contractile rhythm within the digestive tract.

How to Use Дицетел: Administration Guidelines

Дицетел (Pinaverium Bromide) is administered strictly via the oral route using film-coated tablets, which are typically available in 50 mg and 100 mg strengths. The usage protocol involves specific procedural steps to ensure proper application.

---

Dosing and Frequency

Feature	Instruction
Standard Adult Dose	Typically 50 mg three times per day, or 100 mg two or three times per day.
Maximum Daily Dose	Dosage may be increased to a maximum of 300 mg per day in exceptional cases.
Administration Timing	Must be taken with a meal or in the middle of a meal and a full glass of water.
Age-Group Rules	The medication is not recommended for use in children and adolescents under 18 years of age.

---

Administration Procedure

Correct administration follows specific steps:

1. The tablet must be swallowed whole and should not be chewed, crushed, or sucked.
2. Take the tablet with a large glass of water (e.g., 240 mL) to facilitate safe passage through the esophagus.
3. Remain in an upright position (sitting or standing) while taking the tablet and for approximately 30 minutes afterward.
4. If a dose is missed, take it as soon as possible, unless it is almost time for the next scheduled dose; in that case, skip the missed dose and do not double the dose to catch up.

These instructions define the approach for the administration of this product. The duration of treatment is determined by the specific functional disorder being managed.

Research Evidence / Overview of Studies for Дицетел

---

Evidence for Use in Irritable Bowel Syndrome (IBS)

The research into the use of this medicine for Irritable Bowel Syndrome (IBS) primarily involves numerous short-term Randomized Controlled Trials (RCTs). These studies were designed to evaluate the short-term changes observed in patient-reported outcomes, and their data has been consolidated into systematic reviews and meta-analyses to examine overall group patterns. Researchers have applied these studies to adult populations diagnosed with IBS. Findings describe patterns observed where patient-reported outcomes describing perceived discomfort were recorded over the short, defined time intervals, indicating measured changes in abdominal pain and patient-reported shifts in functional measures like quality of life scores. However, the available research is limited by its short follow-up duration, and results apply only to the populations studied under the specific conditions of the trials.

---

Research on Functional Gastrointestinal Motility Disorders

This area of research focuses on the medicine's role in conditions characterized by fluctuating or episodic manifestations throughout the gastrointestinal tract. Studies explored how the medicine was observed in observational settings, evaluating daily-life functioning and outcomes reflecting activity level during periods of symptom activity. The evidence contributes to understanding symptom patterns related to conditions marked by functional limitations.

---

Studies on Functional Biliary Disorders and Diagnostic Procedures

Research into functional biliary disorders is characterized by smaller clinical studies and physiological studies. These studies primarily monitored physiological outcomes, such as pressure readings within the common bile duct, in contexts involving temporary physiological changes. Research has also examined the use of the medicine acutely for diagnostic procedures, such as before or during an Endoscopic Retrograde Cholangiopancreatography (ERCP), looking at outcomes like technical success rates. Data for sustained symptom management in this condition remains limited.

---

Long-Term Studies and Durability of Symptom Measurement

Most pivotal clinical trials involving this medicine focused on short-term symptom changes, with follow-up durations typically limited to only a few weeks. Consequently, research has not yet established the full durability of measured symptom patterns or the persistence of patient-reported experiences over extended periods. Long-term effects are not fully established, and studies help show what has been observed so far, but long-term symptom evolution is not well characterized.

---

Evidence Gaps and Areas of Research Uncertainty

Research highlights what is known and what is still uncertain. One significant limitation is that the follow-up durations were limited in many of the key studies. While findings indicate patterns related to short-term changes, some older evidence includes modest sample sizes. Comparative evidence directly contrasting this medicine with other treatments in the same class remains limited, and subgroup findings across all IBS classifications are also uncertain in the broader evidence landscape.

Key Studies & References

1. Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction (NCT02660143)
2. Pinaverium Bromide Tablets (Official Product Monograph/Labeling used for regulatory context)

Common questions about Дицетел (FAQ)

Q: How should I safely dispose of expired Dicetel tablets?

Official disposal guidelines state that unused or expired Дицетел should not be flushed down the toilet, poured down a drain, or placed in household garbage. Regulatory guidelines suggest returning unused medicine to a pharmacy or community drug take-back program for proper environmental handling. If a take-back program is unavailable, guidelines advise mixing the tablets with an undesirable substance, like used coffee grounds or kitty litter, sealing the mixture in a bag, and then discarding it in the household trash.

---

Q: What is the maximum duration I can take Дицетел for IBS symptoms?

The official product information does not specify a single maximum treatment length for all individuals. Treatment duration is based on the functional disorder being managed, and a healthcare professional determines the appropriate duration of treatment based on the individual condition. Regulatory reviews show that most pivotal clinical trials focused on short-term symptom changes, often limited to a few weeks.

---

Q: What should I do if I accidentally miss a dose?

Product instructions state that a missed dose should be taken as soon as it is remembered. However, if it is already almost time for the next scheduled dose, the missed dose should be skipped entirely. Official information emphasizes the importance of not taking a double dose to compensate for the one that was missed.

---

Q: Is Дицетел available over the counter (OTC) or only by prescription?

Дицетел (Pinaverium Bromide) is classified by regulatory authorities as a prescription-only medicine. It requires a prescription from a licensed healthcare provider and is not available for purchase over the counter.

---

Q: Does Dicetel have a sedative effect that could affect driving or operating machinery?

Official safety documents list central nervous system effects such as drowsiness (somnolence) and headache as common side effects of Дицетел. If these effects, or any dizziness, are experienced, they may affect the ability to drive or operate complex machinery safely. Patients who experience these effects are advised to use caution before attempting such activities.

Official Storage and Disposal Requirements

Dicetel film-coated tablets must be stored according to regulatory standards to ensure product stability and safety.

Requirement Type	Official Classification
Storage Temperature	Controlled Room Temperature (15 C to 30 C)
Environmental Protection	Protect from light and moisture.
Container Rule	Keep in its original packaging (e.g., blister pack).
Child Safety	Keep out of the reach of children and pets.

Handling and Stability: The medication must be kept in a secure, dry place away from excessive heat or direct sunlight, which could compromise the product's 36-month shelf life. Do not use the tablets past their expiry date.

Disposal Instructions: Unused or expired Dicetel must not be discarded into wastewater (flushed down the toilet or poured down a drain) or placed in household garbage. The proper disposal method is to return the unused medication to a pharmacy or community drug take-back program for safe, environmentally responsible handling.